Sandoz introduces authorized generic version of Famvir®
Princeton, New Jersey; March 24, 2011 - Sandoz today announced the introduction of famciclovir tablets, an authorized generic version of Famvir®, in the US. Famvir is currently marketed by Novartis Pharmaceuticals Corporation.
Famciclovir is an antiviral therapy intended for the treatment or suppression of recurrent genital herpes or treatment of recurrent cold sores in patients with healthy immune systems, as well as the treatment of shingles or herpes simplex infections of the skin and mucosa in HIV-infected patients.
"Sandoz is committed to expanding our portfolio of affordable, high-quality treatment options for US patients," said Don DeGolyer, President of Sandoz Inc. "We are pleased to work together with our Novartis Pharmaceuticals Corporation colleagues to bring to market this authorized generic version of Famvir."
According to IMS Health, US sales for famciclovir were approximately USD 198 million for the 12 months ending January 2011. Sandoz is marketing famciclovir in 125 mg, 250 mg, and 500 mg strength tablets.
The foregoing release contains forward-looking statements that can be identified by terminology such as "introduces," "introduction," "committed," or similar expressions, or by express or implied discussions regarding potential future revenues from famciclovir. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of the Company regarding future
events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.